OLMA — Olema Pharmaceuticals Inc

Olema Pharmaceuticals Inc (OLMA) is a biotechnology company listed on NASDAQ. It is led by Sean P. Bohen M.D., Ph.D., based in 780 Brannan Street, San Francisco, CA, United States, 94103, with about 137 employees. Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Net income was -$116.4M. OLMA currently screens at market cap $824.6M.

Use this OLMA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the OLMA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the OLMA SEC filings page. Lician reads the product cache first so this HTML stays unique to Olema Pharmaceuticals Inc even when a live quote feed is slow.